Translational Working Groups
What is a Translational Working Group?
The Translational Working Groups (TWGs) are a mechanism to foster interprogrammatic and translational research to promote new discoveries. TWGs organize MCC members from various research programs into groups designed to address site-specific cancers, foster collaborations, and provide the necessary scientific and clinical expertise to improve outcomes for the specific disease sites.
What does a TWG do?
- Focuses on one type, or a group of closely related types, of cancer
- Applies the scientific findings of our programs to specific types of cancer
- Enhances interactions between MCC members to address disease-specific questions
- Provides the structure to allow MCC investigators opportunities to interact and discuss specific clinical problems and priorities, which can lead to novel approaches to cancer prevention or treatment, and to identifying potential areas of collaboration
- Catalyzes new multi-investigator, multidisciplinary preclinical and clinical translational research
- Communicates with University of Minnesota Foundation development officers and craft literature describing efforts in research area
- Advises the MCC director and executive committee on spending philanthropic funds designated for a TWG site-specific cancer
- Advises program leaders and members on clinical resources for research in TWG cancer types
- Provides a “front door” for philanthropists and community members interested in site specific cancers
Our Translational Working Groups
Brain Tumor TWG
Brain cancer that originates in the tissue of the brain is called primary brain cancer. Cancer that begins elsewhere in the body and spreads to the brain is known as metastatic or secondary brain cancer. Metastatic brain tumors are the most common brain tumors. Our neuro-oncology specialists treat patients with a broad spectrum of noncancerous (benign) and cancerous (malignant) tumors of the brain and nervous system. The Brain Tumor TWG team brings together experts from basic science, to clinical research, to translational research, and to the patient to create truly comprehensive care.
Administrative Contact: Elizabeth Fedie, MPNA – email@example.com – 612-624-0653
Breast Cancer TWG
Breast cancer forms in the tissue of the breasts, usually in the tubes that carry milk to the nipple (ducts) or the glands that produce milk (lobules). Each cancer behaves differently, and accurately identifying the cancer is essential to effective treatment. The Breast Cancer TWG takes an innovative approach to care, participating in clinical trials for the prevention and treatment of cancer, as well as testing the effectiveness of hormone-blocking or dietary interventions.
Administrative Contact: Jean Jacoby – firstname.lastname@example.org – 612-626-5475
Genitourinary Tumors TWG
Genitourinary cancers include a variety of cancers that are found in the male and female urinary tract, including the bladder, kidneys and ureters. They are also found in the male reproductive organs, including the prostate, testicles and penis. The Genitourinary Tumors Translational Working Group has served as leaders in genitourinary cancer diagnosis and treatment for many years. Our program pioneered endoscopic urology using percutaneous approaches to biopsy masses in the kidney. In addition, the prostate-specific antigen test was first validated at the University of Minnesota as a marker for prostate cancer.
Administrative Contact: Liz Mayock – email@example.com – 612-625-7486
Gynecologic Cancers TWG
Gynecologic cancers are cancers that occur in the female reproductive organs, including the following: vulva, vagina, cervix, uterus, fallopian tube, ovary, and primary peritoneal cancer. As one of the largest gynecologic cancer services in the Midwest, we provide comprehensive care and access to the latest in research, as well as new approaches to treating gynecologic cancers. We were named a National Center of Excellence in Women’s Health by the Office of Women’s Health at the U.S. Department of Health and Human Services.
Administrative Contact: Matt Gerber – firstname.lastname@example.org – 612-624-9486
Heme Malignancy TWG
Heme Malignancies are cancers that affect the body's bone marrow, blood cells, lymph nodes and other parts of the lymphatic system. They’re also known as blood cancers. Blood cancers are typically classified into four categories: Leukemia, Lymphoma (Hodgkin and non-Hodgkin lymphoma), Myeloma, and Myelodysplastic syndromes. We have an internationally recognized team of blood cancer experts known for their expertise in treating all forms of blood cancer.
Administrative Contact:Ginny Oie – email@example.com – 612-626-2902
Sarcoma cancers, also known as musculoskeletal or bone and soft tissue cancers, develop in the body’s connective tissue, such as: fat, blood vessels, nerves, bones, muscles, tendons, and cartilage. A multidisciplinary team works with patients to develop a customized treatment plan. We are continually improving treatment for patients with bone and soft tissue cancers through laboratory work, clinical research and education.
Administrative Contact: Rick Jacobson – firstname.lastname@example.org – 612-626-5501
May 28, 2014: Masonic Cancer Center Sarcoma Translational Working Group Retreat
8:20 a.m. – 1 p.m., MCRB 450
Session 1: Open to all university community, Foundation and philanthropic partners
8:30 – 11:55 a.m.
Research presentations by program members
12- 1 p.m.
Development of novel combination targeted therapies for pediatric sarcomas Lee J. Helman, M.D. Pediatric Oncology Branch, Head, Molecular Oncology Section, Scientific Director and Senior Investigator, Center for Cancer Research, National Cancer Institute
Session 2: Program retreat for Sarcoma TWG members only.
RSVP before 4 p.m. on Monday, May 26, 2014 by email to email@example.com.
Thoracic cancers include cancers of the lungs, bronchial tubes, and esophagus. Our lung and esophageal cancer specialists are experts in treating lung cancer and all chest-related cancers. Patients with lung and esophageal cancers often have complex medical needs and require comprehensive therapies. Our lung and esophageal cancer specialists see more than 1,000 patients each year and work with them to develop a customized treatment plan.
Administrative Contact: Barbara Porwit – firstname.lastname@example.org – 612-624-5620